Safety, Tolerability and Performance of SmartMatrix Dermal Replacement Scaffold

Inclusion Criteria:

• Male or female, at least 18 years of age
• Suspected or histologically proven BCC or SCC
• Suspected or histologically proven BCC or SCC ≥1cm ≤3cm in diameter on either leg
• Expected defect following surgery ≥3cm, ≤6cm in diameter
• Patient or authorised representative able to comprehend and sign the Informed Consent prior to enrolment in the study

Exclusion Criteria:

• Aged <18 years of age
• Pregnant or lactating females
• Skin lesion >4cm in diameter or size that will result in post-surgical defect >6cm in diameter
• Lesion located over joint, i.e. ankle or knee
• Patient who are smokers
• Diabetic patients
• Patients diagnosed with peripheral vascular disease or venous stasis
• Patients receiving regular systemic steroids
• Patients who are immuno-compromised (either acquired or congenital)
• Patients with a known coagulopathy (either acquired or congenital) but not including patients on aspirin or other anti-platelet therapy
• Patients who have received radiotherapy treatment to the area about to be treated with Smart Matrix
• Concurrent participation in another experimental intervention or drug study
• Unwilling or unable to provide informed consent